Biotech by one-year price change
How far the share price has moved over the last 52 weeks.
Moderna leads the 24 biotech ranked by one-year price change, at +755%, ahead of Kodiak Sciences (+396%) and Twist Bioscience (+340%). Figures as of 18 Nov 2026, 16:15 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Moderna+755%
- Median
- +40.0%
- Combined market value
- PLN 3.38T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | 1 year ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ModernaMRNA · Health Care | +755% | PLN 326.8B | PLN 807.70 | 2.96% down | 755% up | ||
| 2 | Kodiak SciencesKOD · Health Care | +396% | PLN 25.3B | PLN 387.26 | 0.60% down | 396% up | ||
| 3 | Twist BioscienceTWST · Health Care | +340% | PLN 31.5B | PLN 462.64 | 2.63% up | 340% up | ||
| 4 | ImmunityBioIBRX · Health Care | +193% | PLN 28.3B | PLN 26.56 | 5.43% up | 193% up | ||
| 5 | Revolution MedicinesRVMD · Health Care | +131% | PLN 139.3B | PLN 643.96 | 1.65% down | 131% up | ||
| 6 | Adaptive BiotechnologiesADPT · Health Care | +88.1% | PLN 18.3B | PLN 113.13 | 1.33% down | 88% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | +87.5% | PLN 41.5B | PLN 485.78 | 0.67% down | 87% up | ||
| 8 | CG OncologyCGON · Health Care | +85.3% | PLN 28.6B | PLN 320.33 | 0.82% up | 85% up | ||
| 9 | ExelixisEXEL · Health Care | +62.6% | PLN 67.7B | PLN 277.38 | 0.61% up | 63% up | ||
| 10 | BiogenBIIB · Health Care | +49.3% | PLN 148.4B | PLN 1,003.97 | 0.53% down | 49% up | ||
| 11 | Krystal BiotechKRYS · Health Care | +46.3% | PLN 36.8B | PLN 1,241.89 | 3.35% up | 46% up | ||
| 12 | ImmunovantIMVT · Health Care | +43.4% | PLN 28B | PLN 135.37 | 1.28% up | 43% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | +36.6% | PLN 44.5B | PLN 390.14 | 1.01% up | 37% up | ||
| 14 | AmgenAMGN · Health Care | +33.7% | PLN 972.6B | PLN 1,798.00 | 2.44% down | 34% up | ||
| 15 | Gilead SciencesGILD · Health Care | +32.9% | PLN 841.2B | PLN 678.23 | 1.02% down | 33% up | ||
| 16 | Bio-TechneTECH · Health Care | +25.6% | PLN 46B | PLN 292.70 | 0.13% up | 26% up | ||
| 17 | VaxcytePCVX · Health Care | +22.2% | PLN 37.5B | PLN 237.12 | 0.82% down | 22% up | ||
| 18 | Neurocrine BiosciencesNBIX · Health Care | +20.2% | PLN 66.2B | PLN 653.63 | 2.12% down | 20% up | ||
| 19 | Scholar Rock HoldingSRRK · Health Care | +13.6% | PLN 23.2B | PLN 190.49 | 4.99% up | 14% up | ||
| 20 | QiagenQGEN · Health Care | +12.0% | PLN 41.2B | PLN 199.49 | 0.37% down | 12% up | ||
| 21 | RepligenRGEN · Health Care | +4.58% | PLN 43.9B | PLN 686.50 | 5.17% up | 5% up | ||
| 22 | argenxARGX · Health Care | +3.60% | PLN 239.4B | PLN 3,807.24 | 0.16% down | 4% up | ||
| 23 | BioNTechBNTX · Health Care | -16.3% | PLN 83.8B | PLN 338.09 | 1.01% down | 16% down | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | -20.9% | PLN 16.1B | PLN 166.34 | 2.94% up | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0247 PLN).
Questions and answers
Which biotech rank first by one-year price change?
Moderna (+755%), Kodiak Sciences (+396%) and Twist Bioscience (+340%) are the top three of the 24 biotech ranked by one-year price change as of 18 Nov 2026, 16:15 UTC.
How many biotech are in this ranking?
24 are ranked by one-year price change.
What are these biotech worth together?
The 24 biotech ranked by one-year price change have a combined market value of PLN 3.38T as of 18 Nov 2026, 16:15 UTC.
What does ranking by one-year price change measure?
How far the share price has moved over the last 52 weeks.
Learn how this ranking works
All markets guides →- 52-week high and low: what the range tells you
A stock's 52-week high and low are the highest and lowest prices it reached over the past year. Where today's price sits in that range, from 0% at the low to 100% at the high, shows how the past year has gone. Sources differ on whether they use closing or intraday prices, so the same stock's range can differ slightly.
- Drawdown and recovery: why a 50% fall needs a 100% gain
A drawdown is how far a price has fallen from its previous peak, as a percentage of that peak. Recovery needs a larger gain than the fall, because the gain starts from a smaller base: a 20% drop needs a 25% rise to get back, a 50% drop needs 100%, and a 75% drop needs 300%.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by one-year price change”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=year-change
Underlying data: Yahoo Finance; SEC EDGAR.